Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer

被引：0
|
作者：
Ko, J. [1 ]
Kim, Y. [1 ]
Park, M. [1 ]
Cui, Z. [1 ]
Ahn, M. [1 ]
Park, K. [1 ]
机构：
[1] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 09期
关键词：
D O I：
10.1016/S1359-6349(08)71288-6
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：29 / 30
页数：2
相关论文
共 50 条
  • [1] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Otsuka, Kyoko
    Hata, Akito
    Takeshita, Jumpei
    Okuda, Chiyuki
    Kaji, Reiko
    Masago, Katsuhiro
    Fujita, Shiro
    Katakami, Nobuyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 835 - 841
  • [2] EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer
    Kyoko Otsuka
    Akito Hata
    Jumpei Takeshita
    Chiyuki Okuda
    Reiko Kaji
    Katsuhiro Masago
    Shiro Fujita
    Nobuyuki Katakami
    [J]. Cancer Chemotherapy and Pharmacology, 2015, 76 : 835 - 841
  • [3] Apatinib combined with EGFR-TKI in treating advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    Guo, W.
    Guo, Y.
    Zhang, X.
    Zhu, H.
    Shen, F.
    Xu, J.
    Zhang, X.
    Wang, R.
    Ren, X.
    Li, J.
    Song, X.
    [J]. ANNALS OF ONCOLOGY, 2019, 30
  • [4] EGFR-TKI rechallenged treatment combined with apatinib in non-small cell lung cancer with EGFR-TKI resistance.
    Liang, Li
    Li, Fang
    Cao, Baoshan
    Zhang, Zhaohui
    Zhu, Xiang
    Wang, Jiadong
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [5] Efficacy and safety of apatinib plus EGFR-TKI in advanced non-small cell lung cancer with EGFR-TKI resistance
    Tian, R.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S980 - S981
  • [6] Epithelial-mesenchymal transition is associated with osteopontin-induced EGFR-TKI resistance in EGFR mutant non-small cell lung cancer
    Chen, Junjie
    Shi, Lin
    Qian, Yao
    Jin, Yi
    Dong, Nian
    Chen, Chengshui
    Wang, Beibei
    [J]. JOURNAL OF THORACIC DISEASE, 2023, 15 (06) : 3359 - +
  • [7] The reversible resistance mechanisms of second generation EGFR-TKI, Dacomitinib, in non-small cell lung cancer
    Haga, Yuya
    Tsutsumi, Yasuo
    [J]. CANCER SCIENCE, 2023, 114 : 1071 - 1071
  • [8] Neoadjuvant EGFR-TKI therapy in Non-Small cell lung cancer
    Grant, Christopher
    Nagasaka, Misako
    [J]. CANCER TREATMENT REVIEWS, 2024, 126
  • [9] Advances in the management of acquired resistance to EGFR-TKI in non-small cell lung cancer
    Fei Zhou
    Caicun Zhou
    [J]. Oncology and Translational Medicine, 2015, 1 (01) : 20 - 25
  • [10] REBIOPSY IN NON-SMALL CELL LUNG CANCER PATIENTS WITH ACQUIRED RESISTANCE TO EGFR-TKI
    Yamauchi, Hiroyoshi
    Nakayama, Masayuki
    Yamamoto, Shinichi
    Saito, Tatsuya
    Okuyama, Akiko
    Mato, Naoko
    Yamasawa, Hideaki
    Suzuki, Takuji
    Bando, Masashi
    Hagiwara, Koichi
    [J]. RESPIROLOGY, 2017, 22 : 242 - 242
12345